The FLRG gene encodes a secreted glycoprotein that binds to activin and is highly homologous to follistatin, an activin ligand. We cloned the promoter region of the human FLRG gene, and de®ned the minimal region necessary for transcription activation in a reportersystem assay. We showed that the fragment between positions 7130 and +6, which consists of multiple consensus Sp1-binding sites, is required for the constitutive expression of the FLRG gene. We demonstrate here that FLRG mRNA expression is rapidly induced by TGFb or by transfection with Smad protein expression vectors in human HepG2 cells. We investigated the transcription-regulation mechanism of FLRG expression in HepG2 cells following treatment with TGFb. By deletion and point-mutation analysis of the FLRG promoter, we identi®ed a Smad-binding element involved in the TGFb-inducible expression of the FLRG gene. Moreover, transactivation of the FLRG promoter by TGFb was compromised by dominant-negative mutants of Smad3 and Smad4 proteins. In addition, gel electrophoresis mobility-shift assays demonstrated the speci®c interaction of Smad3 and Smad4 proteins with the Smad-binding element consensus motif found in the FLRG promoter. Taken together, our data imply that Smad proteins participate in the regulation of expression of FLRG, a new target of TGFb transcription activation. Oncogene (2001) 20, 5409 ± 5419.
Introduction
We have already reported the molecular characterization of a t(11;19)(q13;p13) translocation in B-cell chronic lymphocytic leukemia, which led to the identi®cation of a new evolutionarily-conserved gene, the Follistatin-related gene (FLRG), located on chromosome 19 at band 19p13 (Hayette et al., 1998) . In normal human tissues the highest steady-state levels of FLRG transcripts have been observed in the placenta, amniocytes, chorionic villosities and bone marrow stromal cells. FLRG encodes a secreted glycoprotein which is highly homologous to follistatin, most of whose eects are mediated by its binding with activin, a member of the transforming growth factor-b (TGFb) superfamily of growth/dierentiation factors. The biological activity of activin, in a broad range of cells, is antagonized by follistatin (Phillips and de Kretser, 1998; Ying et al., 1997) . These cytokines have multifunctional properties, and are important local regulators of growth and dierentiation in a variety of tissues at various stages in the life cycle (DePaolo, 1997) . Activin, produced by bone marrow stromal cells (Yamashita et al., 1992) such as FLRG, is also involved in the regulation and development of hematopoietic progenitor dierentiation (Johansson and Wiles, 1995; Yu and Dolter, 1997) , particularly in the erythroid lineage (Kitamura et al., 2000; Shao et al., 1992; Shiozaki et al., 1992) . It was the strong homology between follistatin and FLRG that led to our demonstration that FLRG, like follistatin, interacts physically with activin (Maguer-Satta et al., 2001) . The interaction of FLRG with activin suggests that FLRG could be involved in the regulation of the biological activity of activin, in particular in hematopoiesis. We have previously analysed FLRG expression in the hematopoietic system and shown that FLRG and activin were expressed in the same cells, and that they were up regulated during hematopoiesis. Moreover, in human bone marrow stromal cells, FLRG mRNA expression was rapidly induced by TGFb (MaguerSatta, et al., 2001) , a cytokine known to be involved in the regulation of cell proliferation and dierentiation during hematopoiesis (Dybedal and Jacobsen, 1995; Krystal et al., 1994; Pierelli et al., 2000) .
TGFb exerts a wide range of biological eects on a large variety of cell types, e.g. growth control, matrix production, cell adhesion and migration (Kingsley, 1994) . The transduction of the TGFb signal is initiated by its binding to the heteromeric complex of type I and type II receptors, both of which exhibit serine/ threonine kinase activity. Following ligand binding, the type II receptor phosphorylates and thereby activates the type I receptor cytoplasmic domains.
Signaling from the receptor to the nucleus is mediated by the phosphorylation of cytoplasmic mediators, the Smad proteins Massague and Wotton, 2000; Wrana, 2000) . The identi®cation of Smad proteins as critical intracellular mediators of TGFb superfamily-transcriptional responses has contributed greatly to an understanding of how this family of cytokines produces their biological eect (Derynck et al., 1998) . When phosphorylated by the activated receptors, Smad proteins transduce signals to the nucleus via homo-and heterooligomeric interactions. They activate the transcription of target genes in a celltype-speci®c manner through interaction with DNA and with other nuclear factors (Massague and Wotton, 2000; ten Dijke et al., 2000) . Regulation of the transcription of speci®c sets of genes by TGFb mediates many of these physiological roles. To date, few of these transcriptional targets have been identi®ed. Molecular characterization of the mechanisms involved in the regulation of TGFb-responsive genes should provide an insight into TGFb physiological role.
The aim of this study was to characterize the FLRG minimal promoter and to analyse its transcriptional regulation by TGFb. FLRG is expressed as two major transcripts of 2.5 and 1.2 kb (Hayette et al., 1998) . Here we show that the two FLRG transcripts were initiated at the same transcription start site, and that their transcription was directed by the same promoter. We cloned the promoter region of the human FLRG gene and de®ned the minimal region necessary to transcription activation in a reporter-system assay. The human hepatoma HepG2 cells respond to a variety of growth factors such as TGFb, and in this study we found that TGFb dramatically increased FLRG mRNA expression in these cells. We characterized the regulation of the expression of FLRG by TGFb at the transcriptional level, and showed that TGFb upregulates FLRG expression through the action of Smad proteins, as demonstrated by FLRG promoter-reporter constructs, Northern blot, and electrophoretic mobility-shift assays.
Results and discussion

Differential polyadenylation of FLRG
We previously showed that FLRG is expressed as two major transcripts of 2.5 and 1.2 kb (Hayette et al., 1998) . The 2.5 kb transcript (accession No. U76702) is the most abundant. To ®nd out whether the shorter 1.2 kb transcript results from alternative transcription initiation or post-transcriptional modi®cation such as polyadenylation and splicing, we screened a human cDNA library, using a fragment of the 5' end region of the 2.5 kb cDNA as a probe. Of 24 positive clones, eight did not hybridize to a probe speci®c of the 3' untranslated region of the 2.5 kb cDNA. Restriction mapping and partial sequences showed that all of them contained sequences coding from exon 1. The two longest clones were entirely sequenced; they were identical to the region encompassing nucleotides 1 ± 1139 on the 2.5 kb transcript. Strangely, there was no recognizable polyadenylation sequence (AATAAA) in the sequence of the short transcript, but a close variant, GATAAA, was found at position 1112. A poly(A) tail of 48A was found at the 3' end of the cDNA, indicating that polyadenylation had occurred. The lack of the canonical AATAAA motif in a short transcript, coding for the same protein as the long transcript, has already been reported for other genes such as the human cyclin D1 (Xiong et al., 1991) .
In summary, nucleotide sequence analysis revealed that the two FLRG transcripts had the same 5' end, and coded for the same protein. The smaller transcript corresponded to a shortened form of the 2.5 kb transcript resulting from the use of a dierent polyadenylation signal. These results indicate that both FLRG transcripts were initiated at the same transcription start site, and that their transcription was directed by the same promoter.
The 5' flanking region of the human FLRG gene exhibits promoter activity in HepG2 cells
In order to study the transcription regulation determining FLRG gene expression, we cloned and analysed the promoter activity of this gene. The 5400-bp human genomic DNA fragment containing sequences upstream from the FLRG cDNA was cloned from a human genomic library. The complete sequence of this region was found in GenBank under the description of the cosmid R33586 localized on chromosome 19 and containing the FLRG gene (accession No. AC004156). The promoter activity of this sequence was tested in transient transfection experiments in HepG2 cells using two reporter plasmids (pGL3-basic and pGL3-MLP) which contain dierent regions of the FLRG putative promoter in front of a luciferase reporter gene. The FLRG sequence, extending from positions 75386 to +6 relative to the major transcription start site (cloned into the pGL3-basic plasmid) mediated transcriptional activity in HepG2 cells (Figure 1a ). In addition, transfection of HepG2 cells with a pGL3-basic plasmid containing the fragment extending from positions 7398 to +6 resulted in a high level of luciferase activity ( Figure 1a) . The level of transcriptional activity observed with the 7386 to +6-bp region is higher than the one obtained with the 75386 to +6-bp region suggesting the existence of putative inhibitory elements in the 75386 to 7398-bp region.
These assays indicate that the promoter sequence from positions 7398 to +6 is sucient to mediate the transcriptional activation of the FLRG gene. Computer-assisted analysis revealed that this fragment ( Figure  1b) did not contain the canonical CAAT box, but that it did exhibit several features of a promoter: a putative TATA homology element (in the noncoding strand at nucleotide 749) and a GC-rich¯anking area (83% G/ C between 7130 and +6). There are four sequence motifs, at positions 7114, 795, 783 and 778, which exactly match the recognition sequence of the transcription factor Sp1 in this sequence. Sp1 is a ubiquitously-expressed transcription factor with a zinc-®nger DNA-binding domain that recognizes G/ C-rich DNA sequences. Sp1 produces its transcriptional properties by interacting directly with factors of the basal transcription machinery and cooperating with several transcriptional activators (Cook et al., 1999; Suske, 1999) .
To test the possibility that the Sp1 consensus sites may be involved in the mediation of FLRG promoter induction, various FLRG promoter fragments were cloned into the pGL3-MLP vector. The transcriptional activation induced by the sequence extending from positions 75386 to +6 was severely impaired by the deletion of the sequence between 7398 and+6 ( Figure  1c ). The highest level of transcriptional activity in HepG2 cells was obtained with the reporter construct containing the 7130/+6 region, which contains all the Sp1 consensus sites. We deleted these Sp1 sites of the FLRG promoter in the pGL3-MLP(7130/+6). Deletion of these sites in the pGL3-MLP(7130/+6;DSp1) construct reduced the activity of the reporter to almost the background level ( Figure 1c ). Our initial functional characterization of the FLRG promoter suggests, that the proximal 7130 to +6-bp region, which contains multiple Sp1-binding consensus sites, is required for constitutive FLRG promoter activity in hepatocytes, and that it contains an endogenous transcription initiation site controlled by the basic transcriptional machinery.
TGFb up-regulates FLRG expression at a transcriptional level in hepatocarcinoma cell lines
We have previously reported that both FLRG mRNA and protein were dramatically increased by TGFb in human bone marrow stromal cells (Maguer-Satta et al., Here we investigated whether TGFb modulated FLRG expression in hepatoma cell lines known to respond to a variety of growth factors such as TGFb. HepG2 and Hep3B cell lines, known to contain functional TGFb receptors, were treated with TGFb for dierent periods of time, and total cellular RNA was analysed by Northern blot using an FLRG cDNA probe. As shown in Figure 2a , TGFb treatment led to an accumulation of both the 2.5 and 1.2 kb FLRG transcripts in these cell lines. We observed a large increase in FLRG mRNA levels 3 h after the addition of TGFb to HepG2 and Hep3B cells. The time-course analysis showed a constant increase in the FLRG mRNA levels over time, the maximal eect being reached after 15 h, declining after longer incubation times.
To make sure that the increased FLRG mRNA levels correlated with an increase in protein synthesis, we performed immunoblotting experiments using a polyclonal antibody directed against FLRG, a secreted glycoprotein which has been shown by Western blot analysis to exist as a 33 kDa form under reducing conditions in the conditioned medium (Hayette et al., 1998) . Figure 2b shows an accumulation of FLRG protein in cell lysate and the conditioned medium from HepG2 cells treated for 48 h with TGFb.
To ®nd out whether the increase in FLRG expression was due to increased FLRG gene expression or to changes in mRNA stability, we analysed FLRG mRNA levels in HepG2 cells treated with the transcription inhibitor actinomycin D in the absence or presence of TGFb. Up-regulation of FLRG by TGFb was abolished by the addition of actinomycin D, suggesting that the increase in mRNA levels was at least partly due to a transcriptional event (Figure 2c ). To make sure that the increase in FLRG expression in the presence of TGFb resulted from increased transcription of the FLRG promoter, we transfected HepG2 cells with the pGL3-MLP(75386/+6) plasmid containing FLRG promoter elements between nucleotides 75386 and +6 driving the expression of the luciferase reporter gene. As shown in Figure 2d , TGFb produced a 3.5-fold induction of luciferase activity, Proteins separated by SDS-12% polyacrylamide gel electrophoresis were immunodetected using the rabbit anti-GST-FLRG antibody. The same blot was probed for actin to control for equal protein loading. (c) Northern blot analysis with a speci®c FLRG cDNA a-32 P-labeled probe using 10 mg of total RNA from HepG2 cells after treatment with TGFb (10 ng/ml) and actinomycin D (10 mg/ml) for the indicated times. Equal amounts of RNA were checked by ethidium bromide (EtBr) staining. (d) Transcriptional activation of FLRG by TGFb. HepG2 cells were cotransfected with the pGL3-MLP(75386/+6) FLRG promoter-luciferase construct together with the pRL-CMV internal control vector. Twenty-four hours before harvesting, the transfected cells were either stimulated by TGFb or left unstimulated, and luciferase activity was determined. The relative luciferase activity is given as the mean+s.d. of an experiment performed in triplicate, representative of three experiments indicating that the increase in luciferase activity re¯ected an increase in de novo transcription of the FLRG promoter in response to the addition of TGFb. All these results indicate that TGFb up-regulates FLRG expression at a transcriptional level in hepatocarcinoma cell lines.
Identification of TGF b-responsive elements in the FLRG promoter
The process of identifying the TGFb-responsive elements in the FLRG promoter began with the cloning of various FLRG promoter 5' deletion fragments in the pGL3-MLP vector. Each construct was then fused with MLP-luciferase at position +6, and deletion constructs of the FLRG gene promoter were transfected into HepG2 cells in the presence or absence of TGFb. Deletions up to position 72306 relative to the initiation site did not signi®cantly change the induction of the FLRG promoter by TGFb (Figure 3a) . By contrast, the deletion of nucleotides 72306 to 71920 signi®cantly reduced the TGFb activation of the FLRG promoter. These results are consistent with the existence of a TGFb-responsive element somewhere between the 72306 and 71920 nucleotides of the FLRG promoter.
Smad proteins are critical components of the TGFb signaling pathway (Massague and Wotton, 2000; ten Dijke et al., 2000) . The MH1 domains of Smad3 and Smad4 is able to bind to speci®c DNA sequences that contain CAGA-or GTCT-like sequences, termed Smad-binding element (SBE). Optimal binding is achieved with the GTCTAGAC sequence (Zawel et al., 1998) , identi®ed by PCR-based oligonucleotide screening using the MH1 domain of Smad3 and Smad4. One or more SBE-like sequences have been identi®ed in the promoters of several TGFb-responsive genes (Dennler et al., 1998; Hua et al., 1999; Jonk et al., 1998; Nagarajan et al., 1999; Vindevoghel et al., 1998) . Transcriptional regulation by TGFb can be achieved by Smad proteins binding directly to this regulatory element within the promoter. Alternatively, Smad proteins can serve as co-activators of transcription through physical interactions and functional cooperation with other DNA-bound transcription factors (Chen et al., 1996a) . Sequence analysis of the 72306 to 71920 region of the FLRG promoter has shown that there is an SBE, AGCCAGACA, at 72028, which perfectly matches the SBE consensus site identi®ed in the human PAI-1 promoter (Dennler et al., 1998) . To explore the biological signi®cance of the SBE in the TGFb-mediated induction of the FLRG promoter, we mutated the AGCCAGACA sequence to AACGCGT in the pGL3-MLP(72306/+6;DSBE) construct. This mutation signi®cantly reduced the luciferase activity of the FLRG promoter in the presence of TGFb by comparison with the pGL3-MLP(72306/+6) construct (Figure 3b ). This result indicates that this consensus Smad-binding motif in the FLRG promoter is involved in TGFb-mediated transcription activation.
Previous studies have shown that overexpression of Smad proteins activates transcription of several genes, in the absence of TGFb (Denissova et al., 2000; Feng et al., 2000; Jonk et al., 1998) . Expression vectors for Smad2, Smad3 and Smad4 activate the luciferase activity of the pGL3-MLP(72306/+6) FLRG promoter construct in the absence of TGFb (Figure 3c ). When the pGL3-MLP(72306/+6;DSBE) mutated construct is cotransfected with Smad2, Smad3 and Smad4 expression vectors, the luciferase activity is signi®cantly reduced. Nevertheless, with the mutated pGL3-MLP(72306/+6;DSBE) construct, a residual induction is observed in the presence of either TGFb or Smad proteins, suggesting the existence of another TGFb-responsive element. Altogether, our results indicate that this consensus Smad-binding motif in the FLRG promoter is involved in TGFb-mediated transcription activation and that Smad proteins are able to activate FLRG transcription via the SBE site located at position 72028. This result is in accordance with previous reports showing that the ability of several genes to respond to TGFb requires the presence of one or more SBE (Dennler et al., 1998; Jonk et al., 1998; Nagarajan et al., 1999; Zhang et al., 2000) .
Several reports on dierent promoters have identi®ed Sp1 sites as major TGFb-responsive promoter elements (Brodin et al., 2000; Feng et al., 2000; Pardali et al., 2000) . To analyse whether the Sp1 DNA binding sequences found on the FLRG promoter are involved in response to TGFb, we generated a reporter construct where the Sp1 sites were deleted. Within the pGL3-MLP(72306/+6) vector containing the SBE site, the region containing the Sp1 consensus sites (nt 7104 to 766) in the FLRG promoter was deleted giving the pGL3-MLP(72306/+6;DSp1) construct. As we observed using the pGL3-MLP(7130/+6;DSp1) construct (Figure 1c) , deletion of the Sp1 sites in the pGL3-MLP(72306/+6;DSp1) vector reduced the basal promoter activity. This deletion signi®cantly reduced the response to TGFb or Smad proteins of the FLRG promoter reporter construct (Figure 3b,c) . As previously reported for Smad7 gene (Brodin et al., 2000) , our results suggest that Sp1 transcription factor is essential for basal transcription and for the optimal inducibility by TGFb of the FLRG promoter.
Regulation of the FLRG promoter by Smad proteins
Having determined that the increase in FLRG transcription by TGFb required an SBE motif, we further analysed the involvement of Smad family proteins in FLRG transcriptional activation. The eects of Smad proteins on the FLRG promoter were examined by cotransfection of HepG2 cells with the pGL3-MLP(73293/+6) promoter-luciferase construct along with expression vectors for Smad2, Smad3 and Smad4, either independently or in combination. As previously shown for other target genes transcriptionally regulated by TGFb (Chen et al., 1996b; Dennler et al., 1998; Nagarajan et al., 1999) , transfection of Smad3 alone can stimulate FLRG promoter activity (Figure 4a) Kardassis, 1998; Nakao et al., 1997) that show a cooperation of Smad2, Smad3 and Smad4 in the TGFb-inducible transcriptional response. The fact that transactivation of the FLRG promoter by Smad proteins was higher than that achieved by TGFb suggests that endogenous Smad proteins are not expressed at saturating amounts in HepG2 cells.
We also examined the possibility that Smad protein expression correlates with induction of FLRG mRNA in HepG2 cells. For this purpose, we transfected expression vectors for Smad2, Smad3 and Smad4 proteins, independently or in combination, into HepG2 cells, and total cellular RNA were analysed by Northern blot analysis using FLRG cDNA as a probe. The expression pattern of endogenous FLRG mRNA (Figure 4b) shows a strong correlation with the results obtained using the FLRG promoter fused to luciferase as a cooperative eect of Smad2, Smad3 and Smad4 was also observed in FLRG mRNA expression.
Further evidence for the involvement of Smad proteins in the TGFb-mediated activation of FLRG promoter was obtained by the use of dominantnegative mutants of Smad3 and Smad4 from which the C-terminus, the MH2 domain, had been deleted. It has already been shown that these carboxyl-terminal truncated mutants can block TGFb signaling through Smad proteins (Lagna et al., 1996; Zhang et al., 1996) . Transfection of Smad3 and Smad4 dominant-negative mutants signi®cantly reduced the TGFb-mediated activation of the FLRG promoter (Figure 4c ). Taken together, our results indicate that Smad proteins are involved in FLRG transcriptional activation by TGFb in HepG2 cells.
Binding of Smad3 and Smad4 to the SBE site
It is well documented that only Smad3 and Smad4 proteins can bind DNA. In order to activate the DNA binding of Smad3, the Smad3 MH1-MH2 interaction must be released. This occurs naturally by the phosphorylation of Smad3 by TGFb-type I receptor or can be achieved arti®cially when the C-terminus, the MH2 domain, is removed (Kawabata et al., 1998; Song et al., 1998 , Zawel et al., 1998 . To ®nd out whether Smad3 and Smad4 proteins could interact directly with the SBE site at position 72028 of the FLRG promoter, we performed an electrophoretic mobility-shift assay (EMSA) using Smad3, Smad3DC and Smad4 GST fusion proteins. We used as probe a DNA fragment of the FLRG promoter (nt 72093 to 71955) containing the wild-type (139-bp) or the mutated (137-bp) SBE site. As expected, the full-length GST-Smad3 protein showed no detectable binding to the probe (data not shown), while the wild-type probe was signi®cantly shifted by the MH2-deletion mutants of Smad3 (Smad3DC) and the full-length Smad4 fusion protein (Figure 5a ). The binding of Smad3 and Smad4 was found to be speci®c, in that no shift was observed with the 137-bp probe containing the mutated SBE site. In addition, no shift was observed when the wild-type or the mutated probes were incubated with GST alone.
Having demonstrated that Smad proteins are able to bind the SBE motif of the FLRG promoter, we investigate whether TGFb induces binding of nuclear proteins to the SBE motif. We performed an EMSA using Mv1Lu cells nuclear extracts, treated or not with TGFb, and using a probe, containing the wild-type or the SBE mutated site, and covering the region between 72034 and 72014 of the FLRG promoter in three copy number. A speci®c TGFb-induced band with retarded mobility was observed using the wild-type probe and nuclear extracts from cells that had been treated with TGFb for 30 min, while no DNA-protein complex was observed with nuclear extracts from untreated cells (Figure 5b ). In addition, no TGFb- To analyse whether Smad proteins are present in nuclear complexes induced by TGFb, antibodies directed against Smad3 were added to the nuclear extracts before the addition of the radiolabeled probe. Smad3 antibody supershifted the TGFb-induced complex, while the negative control Smad7 antibody was unable to do so (Figure 5b) . These results indicate that TGFb induces the formation of a DNA-protein complex containing Smad proteins and involving the Smad-binding motif, which is present in the FLRG promoter.
In conclusion, we are presenting here the ®rst functional characterization of the FLRG promoter. We have shown that the fragment between positions 7130 and +6, which consists of multiple consensus Sp1-binding sites, is required for the constitutive expression of the FLRG gene. Furthermore, our results indicate that TGFb induces the expression of the FLRG gene in hepatoma cells through a transcriptional mechanism, and the Smad proteins are involved in the activation of the FLRG promoter by TGFb. The SBE motif identi®ed at position 72028 of the FLRG promoter matched the consensus site previously described, and can directly associate with Smad3 and Smad4 proteins. Our study provides strong evidence that this SBE is involved in the response of FLRG to TGFb. Thus the FLRG gene can be considered as a new target of TGFb transcriptional activation through the Smad proteins. A functional cooperation and a physical interaction between Smad and Sp1 proteins has been recently documented for TGFb-induced genes such as the cell cycle inhibitors p15(Ink4B) and p21/ Waf1/Cip1 (Feng et al., 2000; Moustakas and Kardassis, 1998; Pardali et al., 2000) . In the case of FLRG, a cooperation between Smad and Sp1 proteins might be involved in the transcription regulation of this gene. Further studies will be required to con®rm this hypothesis.
FLRG protein, known to be highly homologous to follistatin, has also recently been shown to bind to activin, member of the TGFb superfamilly (MaguerSatta et al., 2001) . Follistatin, through its binding to activin, modulates its biological activity in a broad range of cells. This suggests that FLRG may constitute another partner in the regulation of the biological activity of activin (Tsuchida et al., 2000) . TGFb increases the expression of both activin ligands, FLRG and follistatin (Maguer-Satta et al., 2001) . Altogether, these data suggest that FLRG and follistatin might be involved in the biological eects of these TGFb superfamily cytokines. The involvement of FLRG in the cellular response to TGFb and activin, such as cell proliferation and dierentiation, is currently under investigation.
Materials and methods
Cell cultures
The human hepatoma cell lines HepG2 and Hep3B, and the mink lung epithelial cell line Mv1Lu were obtained by American Type Culture Collection (ATCC), and cultured in Dulbecco's modi®ed Eagle's medium containing 10% fetal calf serum, 0.03% L-glutamine, 100 mg/ml penicillin and 100 mg/ml streptomycin sulfate.
cDNA and DNA libraries
A human placental cDNA library in lDR2 phage was obtained from Clontech Laboratories. The human placental Figure 5 Association of Smad3 and Smad4 with FLRG promoter. (a) Binding of Smad3 and Smad4 to the SBE of the FLRG promoter by gel mobility-shift assay. GST, GST-Smad3DC and GST-Smad4 (300 ng/reaction) were incubated with the wildtype 139-bp (SBE-wt) and the mutated 137-bp (SBE-mut) DNA fragments used as probes. (b) An EMSA was performed using labeled probes containing three repeats of the wild-type or the mutated SBE site, as described in Materials and methods. Nuclear proteins (10 mg) were prepared from Mv1Lu cells either treated or not with TGFb for 30 min. The Smad3 antibody was used in the supershift assay to detect the presence of Smad3 protein in the TGFb-induced bands. The anti-Smad7 was used as control. The arrows denote the position of the TGFb-induced complex as well as the position of supershifted DNA-protein complex genomic library cloned in EMBL3 phage (Stratagene) has already been described (Hayette et al., 1998) .
Plasmid constructs
By screening the human placental genomic library with a probe speci®c to the 5' end of human FLRG cDNA, we isolated about 10 kb of the 5' sequence of the FLRG gene and subcloned insert from positive phages into the pBluescript KS (7) vector (Stratagene).
To study the transcriptional regulation of human FLRG gene expression, we subcloned the FLRG promoter extending from positions 75386 to +6 into the pGL3-basic luciferase reporter gene vector (lacking promoter and enhancer sequences; Promega) and into the pGL3-MLP vector containing a minimal promoter consisting of a TATA box and the initiator sequence of the adenovirus major late promoter (MLP), kindly provided by JM Gauthier (Glaxo Wellcome laboratory, Les Ullis, France) (Dennler et al., 1998) . Various FLRG promoter fragments and 5' deletion fragments were cloned into pGL3-basic and pGL3-MLP vectors. Deletions of DNA were obtained by the unidirectional exonuclease III digestion method (Erase-a-base system, Promega). Within the pGL3-MLP(72306/+6) vector, the SBE consensus site in the FLRG promoter was moved by site-directed mutagenesis (PCR based mutagenesis) from 5'-AGCCAGACA-3' to 5'-AACGCGT-3', giving the pGL3-MLP(72306/+6;DSBE) construct. Within the pGL3-basic(7130/+6) and the pGL3-MLP(72306/+6) vectors, the region containing the Sp1 consensus sites (nt 7104 to 766) in the FLRG promoter was deleted using the USE Mutagenesis kit (Amersham Pharmacia Biotech), giving respectively the pGL3-basic(7130/+6;DSp1) and the pGL3-MLP(72306/+6;DSp1) constructs. All the constructs were sequence-checked.
Mammalian expression vectors encoding¯ag-tagged human Smad2, Smad3 and Smad4 were kindly provided by P ten Dijke (Ludwig Institute for Cancer Research, Uppsala, Sweden). Mammalian expression vectors encoding the dominant-negative human Smad3 (DN-Smad3) and Smad4 (DN-Smad4) proteins were kindly provided by R Derynck (University of California, San Francisco, USA).
Bacterial vectors encoding the full length Smad3 and Smad4 proteins and the MH2-deletion mutant of Smad3 (Smad3DC), fused to GST, were kindly provided by A Mauviel (HoÃ pital Saint Louis, INSERM U532, Paris).
Transient tranfections and reporter assays
For transient transfections, HepG2 cells were seeded (1.4610 5 cells per well) in 12-well plates and transfected 48 h later by Exgen 500 (Euromedex, Souelweyersheim, France) with the indicated reporter constructs (1 mg) and the pRL-CMV internal control vector (25 ng) under the control of the cytomegalovirus promoter (Promega). When increasing amounts of Smad-expression vectors were transfected, total DNA was kept constant (1.5 mg) by the addition of an empty vector (pcDNA3.1 wild-type vector, Invitrogen). Ten ng/ml of human recombinant TGFb1 (R&D) were added 24 h after transfection, and after a further 24 h the luciferase activity was quanti®ed in the cell lysates using the Dual Luciferase Assay (Promega). In all the experiments, performed in triplicate, luciferase activity was normalized by reference to the renilla luciferase activity expressed by the pRL-CMV vector.
For Northern blot analysis, HepG2 cells were seeded (4610 5 cells per well) in 6-well plates and transfected 24 h later by Exgen 500 with expression vectors for Smad2, Smad3 and Smad4, either independently or in combination. The same amount of Smad expression vector (650 ng) was transfected in each case, total DNA was kept constant (2 mg) by the addition of an empty vector. Total RNA from transfected cells were extracted 48 h later.
Northern blot analysis
Total cellular RNA was puri®ed by the acid guanidium thiocyanate-phenol-chloroform method. For Northern blot analysis, 10 mg of total RNA were size-fractionated in formaldehyde-1.2% agarose gels and transferred onto nylon ®lters. The probes were labeled with a-32 P-dCTP using the Rediprime labeling kit (Amersham Pharmacia Biotech) and hybridized according to standard procedures. RNA integrity and equal loading was assessed by Ethidium Bromide staining.
Western blot analysis
The conditioned medium from a low-concentration serum culture concentrated ®ve times and cell lysates (40 mg) from HepG2 cells either treated or not treated with TGFb1 (10 ng/ ml) were subjected to electrophoresis on a 12% SDSpolyacrylamide gel. The separated proteins were transferred onto membrane (Millipore) by electroblotting. The ®lters were incubated with the rabbit anti-GST-FLRG antibody (Hayette et al., 1998) and with an anti-actin monoclonal antibody (Roche Molecular Biochemicals). Bound primary antibodies were detected with horseradish peroxydase-labeled anti-rabbit or anti-mouse secondary antibodies, and developed with enhanced chemiluminescence reagents purchased from Amersham Pharmacia Biotech. A pre-immune serum was used as a negative control (data not shown).
Electrophoresis mobility-shift assay
To prepare nuclear extracts, Mv1Lu cells were plated in 10-cm plates and grown to 75% con¯uency. Cells were then incubated in the presence or absence of TGFb (10 ng/ml) for 30 min. Cells, washed in cold phosphate-buered saline, were lysed in hypotonic lysis buer (20 mM HEPES pH 7.9, 20% glycerol, 10 mM NaCl, 1.5 mM MgCl 2 , 0.2 mM EDTA, 0.1% Triton X-100, 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl¯uoride, 1 mM sodium orthovanidate, and protease inhibitors). After 10 min, nuclei were spun down and incubated on ice during 45 min in the same lysis buer containing 500 mM NaCl. The nuclei were lysed by 10 strokes of a Dounce all-glass homogenizer. Supernatants were then clari®ed and protein concentration was determined using a commercial assay kit (Bio-Rad). Full-length Smad3 and Smad4 proteins and the MH2-deletion mutant of Smad3 (Smad3DC) fused to GST were expressed in Escherichia coli. The resulting recombinant proteins were puri®ed over a GSTSepharose column according to the manufacturer's instructions (Amersham Pharmacia Biotech).
Two probes spanning the region of the FLRG promoter between 72093 and 71955 were generated by polymerase chain reaction (PCR), using the pGL3-MLP(72306/+6) or the pGL3-MLP(72306/+6;DSBE) plasmid as a template, and cloned into the pBluescript KS(7) vector (Stratagene). Wild-type 139-bp and mutated 137-bp DNA fragments containing, respectively, the Smad-binding element (SBE) at position 72028 (AGCCAGACA) and the mutated SBE at position 72028 (AACGCGT), excised from Bluescript SK(7) vector by BamHI. Double stranded synthetic oligonucleotides spanning the region between 72034 and 72014 of the FLRG promoter in three copy number, and containing the wild-type or the mutated SBE site, were used as probes in the electrophoresis mobility-shift assay with Mv1Lu nuclear extracts: SBE-wt, 5'-GGCACGCC-AGCCAGACA ATGACCCACGCC AGCCAGACA ATGA-CCCACGCCAGCCAGACAATGA-3', SBE-mut, 5'-GGCA-CGCCAGCTACATAATGACCCACGCCAGCTACATAA -TGACCCACGCCAGCTACATAATGA-3' (sense strands shown; the core binding site is underlined).
The probes were end-labeled by ®lling in using the Kleenow fragment of DNA polymerase (Biolabs) and a-32 PdCTP. The labeled probes puri®ed by push-column chromatography were incubated with equal amounts of nuclear extracts (10 mg) or 300 ng of GST-Smad fusion proteins and 1 mg of polyd1-dC in a total volume of 30 ml of binding buer (hypotonic lysis buer containing 100 mM NaCl). Protein-DNA complexes were resolved on a 5% nondenaturing polyacrylamide gel in 0.56TBE buer and visualized by autoradiography. For supershifts analysis, nuclear extracts were preincubated for 30 min at 378C with 2 mg of antibodies against Smad3 or Smad7 (Santa Cruz Biotechnology), followed by addition of the radiolabeled probes.
